A systematic analysis of WHO cancer medicine modifications reveals a stark evidence deficit: just 11% of recommendations between 2017 and 2023 included cost data, yet African countries adopted approximately 23% of new recommendations into their national essential medicines lists.
This paradox—widespread adoption despite limited economic justification—raises serious sustainability concerns for healthcare systems already operating under severe resource constraints. Researchers examining 160 modifications found that 80% of WHO cancer medicine changes lacked any economic evidence whatsoever. The misalignment between global recommendations and local economic realities suggests that adoption decisions may rely on clinical evidence alone, without adequate consideration of affordability and healthcare budget implications.
The findings underscore an urgent need for economic data integration into global medicine guidance processes.
Was this article helpful?
